Terns Short Term Debt vs Total Assets Analysis
TERN Stock | USD 6.00 0.14 2.39% |
Terns Pharmaceuticals financial indicator trend analysis is much more than just breaking down Terns Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Terns Pharmaceuticals is a good investment. Please check the relationship between Terns Pharmaceuticals Short Term Debt and its Total Assets accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.
Short Term Debt vs Total Assets
Short Term Debt vs Total Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Terns Pharmaceuticals Short Term Debt account and Total Assets. At this time, the significance of the direction appears to have pay attention.
The correlation between Terns Pharmaceuticals' Short Term Debt and Total Assets is -0.88. Overlapping area represents the amount of variation of Short Term Debt that can explain the historical movement of Total Assets in the same time period over historical financial statements of Terns Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Terns Pharmaceuticals' Short Term Debt and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Debt of Terns Pharmaceuticals are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Short Term Debt i.e., Terns Pharmaceuticals' Short Term Debt and Total Assets go up and down completely randomly.
Correlation Coefficient | -0.88 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Short Term Debt
Total Assets
Total assets refers to the total amount of Terns Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Terns Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Most indicators from Terns Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Terns Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.At this time, Terns Pharmaceuticals' Tax Provision is very stable compared to the past year. As of the 28th of May 2024, Selling General Administrative is likely to grow to about 41 M, while Issuance Of Capital Stock is likely to drop about 39.5 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 170K | 2.1M | 12.9M | 13.5M | Net Interest Income | 170K | 2.1M | 12.9M | 13.5M |
Terns Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Terns Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Terns Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 23.9M | 92.3M | 168.1M | 287.0M | 268.5M | 170.3M | |
Other Current Liab | 3.3M | 8.2M | 4.7M | 6.2M | 7.6M | 5.8M | |
Total Current Liabilities | 5.0M | 22.8M | 6.8M | 8.5M | 11.9M | 10.5M | |
Total Stockholder Equity | 4.2M | 68.6M | 160.3M | 276.9M | 255.4M | 153.6M | |
Other Liab | 630K | 877K | 947K | 1.1M | 1.2M | 806.7K | |
Net Tangible Assets | (90.8M) | (117.4M) | 172.2M | 276.9M | 318.5M | 334.4M | |
Property Plant And Equipment Net | 961K | 1.2M | 1.0M | 1.8M | 1.0M | 1.2M | |
Net Debt | (12.3M) | (62.0M) | (47.7M) | (142.0M) | (79.3M) | (83.3M) | |
Retained Earnings | (91.9M) | (131.9M) | (182.1M) | (242.4M) | (332.6M) | (316.0M) | |
Accounts Payable | 1.6M | 935K | 2.1M | 1.6M | 2.5M | 1.8M | |
Cash | 12.3M | 74.9M | 47.7M | 143.2M | 79.9M | 80.8M | |
Non Current Assets Total | 1.7M | 1.4M | 1.1M | 1.8M | 1.1M | 1.4M | |
Non Currrent Assets Other | 719K | 246K | 94K | 37K | 56K | 53.2K | |
Other Assets | 719K | 246K | 94K | 37K | 1.0 | 0.95 | |
Cash And Short Term Investments | 19.7M | 74.9M | 166.0M | 283.1M | 263.4M | 163.9M | |
Common Stock Shares Outstanding | 25.1M | 25.1M | 25.3M | 36.0M | 71.3M | 37.9M | |
Short Term Investments | 7.3M | 0.0 | 118.3M | 139.9M | 183.5M | 192.7M | |
Liabilities And Stockholders Equity | 23.9M | 92.3M | 168.1M | 287.0M | 268.5M | 170.3M | |
Non Current Liabilities Total | 14.7M | 877K | 947K | 1.6M | 1.2M | 1.1M | |
Other Current Assets | 461K | 331K | 948K | 2.1M | 4.0M | 4.2M | |
Other Stockholder Equity | 1.2M | 14.6M | 174.6M | 520.2M | 588.0M | 617.4M | |
Total Liab | 19.7M | 23.7M | 7.8M | 10.1M | 13.2M | 12.2M | |
Net Invested Capital | (90.8M) | (104.6M) | 160.3M | 276.9M | 255.4M | 268.1M | |
Property Plant And Equipment Gross | 961K | 1.2M | 2.2M | 3.2M | 2.6M | 1.9M | |
Total Current Assets | 22.2M | 90.9M | 166.9M | 285.2M | 267.4M | 168.9M | |
Accumulated Other Comprehensive Income | (106K) | (124K) | (338K) | (822K) | (19K) | (20.0K) | |
Net Working Capital | 17.3M | 68.0M | 160.1M | 276.7M | 255.5M | 158.4M | |
Property Plant Equipment | 961K | 1.2M | 1.0M | 757K | 870.6K | 924K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for Terns Stock analysis
When running Terns Pharmaceuticals' price analysis, check to measure Terns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Terns Pharmaceuticals is operating at the current time. Most of Terns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Terns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Terns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Terns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is Terns Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.26) | Revenue Per Share 0.035 | Return On Assets (0.24) | Return On Equity (0.35) |
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.